Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, and its filings offer detailed insight into financial performance, clinical milestones and strategic developments around its WAKIX (pitolisant) franchise and late-stage CNS pipeline.
Recent Forms 8-K filed by Harmony Biosciences report preliminary and actual financial results, such as net product revenue for WAKIX, multi-quarter revenue growth and updated annual guidance ranges. These filings also incorporate press releases and investor presentations that describe the company’s status as a profitable, self-funding biotech with a robust late-stage pipeline, as well as disclosures tied to participation in major healthcare conferences. For investors analyzing HRMY, these documents help contextualize revenue trends, cash generation and spending on research and development, sales and marketing, and general and administrative activities.
Harmony’s 8-K filings also reference significant clinical and regulatory events, including topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome, preannounced WAKIX performance, and updates on Phase 3 and Phase 1 programs such as pitolisant GR, pitolisant HD, EPX-100, EPX-200 and BP1.15205. Through these filings, readers can follow how clinical outcomes, trial initiations and program decisions feed into the company’s overall strategy in sleep–wake disorders, rare epilepsies and neurobehavioral conditions.
On Stock Titan, Harmony Biosciences’ SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, including 8-Ks and, when available, 10-K annual reports, 10-Q quarterly reports and proxy materials. Investors can also monitor insider and executive transaction reports on Form 4 and other ownership filings as they appear in the EDGAR feed. This combination of real-time updates and AI-generated explanations helps users quickly understand the implications of HRMY’s regulatory disclosures without reading every page of each filing.
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.
According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of common stock. The option has an exercise price of $27.74 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market trade.
The option will vest in 36 equal monthly installments beginning on May 2, 2026, meaning the right to exercise the option will phase in gradually over three years.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing lists him as a director of the company but shows no reported transactions or specific share holdings at this time.
Harmony Biosciences Holdings, Inc. is calling a virtual 2026 annual meeting on May 14, 2026 at 1:00 p.m. Eastern Time to consider key governance and compensation matters. Holders of common stock at the March 17, 2026 record date, when 57,867,389 shares were outstanding, may vote online.
Stockholders will vote on electing four Class III directors (Andreas Wicki, Geno Germano, Troy Ignelzi and Ron Philip) to terms ending at the 2029 meeting, ratifying Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approving on a non-binding basis the compensation of named executive officers.
The board, which is largely independent and organized into audit, compensation, and nominating and corporate governance committees, emphasizes pay-for-performance through base salary, annual cash incentives and equity awards. 2025 bonuses for named executives were generally paid at or near target based on revenue, clinical, transaction, financial and talent goals, and the company maintains an anti-hedging policy and a clawback policy on incentive pay.
Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026, and he resigned from the board to assume the executive role. The company also appointed Troy Ignelzi as a Class III director and announced that Antonio Gracias will not stand for re-election at the 2026 annual meeting.
Under his employment agreement, Anastasiou will receive a $600,000 annual base salary, a target annual bonus equal to 55% of salary, and a stock option award with a grant date fair value of $3,700,000, together with severance protections and customary restrictive covenants. Ignelzi will serve on the Audit and Compensation Committees and is deemed an independent director, while the board has nominated Geno J. Germano for election at the 2026 annual meeting.
Harmony Biosciences Holdings Inc: an amendment to a Schedule 13G/A reports that The Vanguard Group holds 0 shares of common stock, representing 0 % of the class. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report beneficial ownership separately.
Harmony Biosciences describes a growing neuroscience business centered on WAKIX, its non-scheduled narcolepsy therapy, and an expanding rare disease pipeline. Net product revenue from WAKIX reached $868.5 million in 2025, within a U.S. narcolepsy market estimated at $3.1 billion.
WAKIX now covers excessive daytime sleepiness and cataplexy in adults and children six and older, with about 8,500 patients on therapy in Q4 2025. The company is advancing next‑generation pitolisant formulations (Pitolisant GR and HD), late‑stage programs in Prader–Willi syndrome and myotonic dystrophy type 1, and a rare epilepsy franchise led by EPX‑100 Phase 3 trials in Dravet and Lennox‑Gastaut syndromes.
Harmony Biosciences Holdings, Inc. reported strong 2025 results driven by its narcolepsy drug WAKIX. Net product revenue reached $868.5 million for 2025, up from $714.7 million, while Q4 2025 revenue was $243.8 million, a 21% year-over-year increase.
GAAP net income was $158.7 million for 2025, or $2.71 per diluted share, compared with $145.5 million, or $2.51 per share, in 2024. Non-GAAP adjusted net income rose to $211.0 million, or $3.60 per diluted share. The company ended 2025 with $882.5 million in cash, cash equivalents and investments, up from $576.1 million.
Harmony reiterated 2026 WAKIX net revenue guidance of $1.0–$1.04 billion, highlighting expectations for blockbuster status in narcolepsy. Management also emphasized a late-stage pipeline, including five Phase 3 trials, a planned pitolisant GR NDA submission targeted for Q2 2026, and an ongoing Phase 1 trial of an orexin-2 agonist.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 3,112,812.16 shares of Harmony Biosciences Holdings, Inc. common stock, representing 5.4% of the class as of the reporting date.
FMR LLC reports sole voting power over 3,109,042 shares and sole dispositive power over 3,112,812.16 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 3,112,812.16 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Harmony Biosciences.